Summary
Our laboratory and others have shown alternative splicing of up to ten exons at a discrete extracellular site to be primarily responsible for the generation of CD44 variant (CD44v) isoforms. Based on clear differences in the expression of these CD44v isoforms between normal and malignant tissues, we believe that elucidation of the mechanisms underlying the regulation of CD44 alternative splicing may provide a new gene therapeutic targeting approach based on CD44 pre-mRNA processingin vivo. This strategy incorporates utilization of CD44 alternative splicing control elements into a chimeric enzyme/prodrug therapy (CEPT), a novel modification of the virus-directed enzyme/prodrug therapy (VDEPT) approach for the treatment of brain metastases from tumors of systemic origin. As initial steps towards the development of a gene therapeutic approach based on targeting tumor cell expression of specific CD44v alternatively spliced isoforms, we have: (1) developed a novelin vivo assay system that allows the rapid analyses of potentially therapeutic CD44 alternative splicing minigene constructs; and (2) cloned theE. coli cytosine deaminase (CD) gene and fused its enzymatically active domain to alternatively spliced CD44 exons (CD44/CD). Deamination of cytosine by this CD44/CD chimeric fusion protein is demonstrated inE. coli cell lysates to be equal to that of wild type cytosine deaminase.
Similar content being viewed by others
References
Gamache FW, Posner JB, Patterson RH: Metastatic brain tumors. In: Youmans GR (ed) Neurological Surgery. Saunders, Philadelphia 2872–2898, 1982
Gagliardi FM, Mercuri S: Single metastasis in the brain: late results in 325 cases. Acta Neurochir 68: 253–262, 1983
Li H, Hamou M-F, de Tribolet N, Jaufeerally R, Hofmann M, Diserens A-C, Van Meir EG: Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53: 5345–5349, 1993
Kaaijk P, Troost D, Morsink F, Keehnen RMJ, Leenstra S, Bosch DA, Pals ST: Expression of CD44 splice variants in human primary brain tumors. J Neuro-Oncol, 1995, this issue
Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Heider K-H, von Ammon K, Wiestler OD, Ponta H, Kleihues P, Herrlich P: Expression of variant CD44 epitopes in human astrocytic brain tumors. J Neuro-Oncol 1995, this issue
Austin EA, Huber BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression ofEscherichia coli cytosine deaminase. Mol Pharmacol 43: 380–387, 1993
Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039–8043, 1991
Richards CA, Huber B: Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by lack of transgene expression. Human Gene Therapy 4: 143, 1993
Huber B, Austin E, Richards C, Davis S, Good S: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cell express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302–8306, 1994
Droll A, Dougherty ST, Chiu RK, Dirks JF, McBride WH, Cooper DL, Dougherty GJ: Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem 270: 11567–11573, 1995
Dougherty GJ, Lansdorp PM, Cooper DL, Humphries RK: Moleculear cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte ‘homing’ receptor expressed by hemopoietic cells. J Exp Med 174: 1–5, 1991
West TP, O'Donovan G: Repression of cytosine deaminase by pyrimidines inSalmonella typhimurium. J Bacteriol 14: 1171–1174, 1982
Sambrook J, Fritsch EF, Maniatis T: Molecular cloning, a laboratory manual. Cold Spring Harbor Laboratory Press, 1989
Schackert G, Price JE, Bucana CD, Fidler IJ: Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer 44: 892–897, 1989
Dertzbaugh MT, Macrina FL: Plasmid vectors for constructing translocational fusions to the β-subunit of cholera toxin. Gene 82: 335–342, 1989
Wales ME, Wild JR: Analysis of structure-function relationships by formation of chimeric enzymes produced by gene fusion. Methods in Enzymology 202: 687–706, 1991
Zdanovsky G, Kulaeva OI, Yankovsky NK: Construction and expression of diphtheria toxin-encoding gene derivatives inEscherichia coli. Gene 116: 81–86, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Asman, D.C., Dirks, J.F., Ge, L. et al. Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element. J Neuro-Oncol 26, 243–250 (1995). https://doi.org/10.1007/BF01052627
Issue Date:
DOI: https://doi.org/10.1007/BF01052627